Compare IX & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IX | HLN |
|---|---|---|
| Founded | 1950 | 2022 |
| Country | Japan | United Kingdom |
| Employees | 51921 | 24524 |
| Industry | Diversified Financial Services | Package Goods/Cosmetics |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0B | 41.1B |
| IPO Year | N/A | N/A |
| Metric | IX | HLN |
|---|---|---|
| Price | $40.16 | $8.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 296.3K | ★ 9.3M |
| Earning Date | 05-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.33% | 1.94% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.73 | $6.55 |
| Revenue Next Year | $4.32 | $4.42 |
| P/E Ratio | ★ $12.93 | $49.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.14 | $8.65 |
| 52 Week High | $40.50 | $11.28 |
| Indicator | IX | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 64.33 | 45.25 |
| Support Level | $37.86 | $8.75 |
| Resistance Level | N/A | $9.29 |
| Average True Range (ATR) | 0.57 | 0.14 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 87.36 | 56.36 |
ORIX Corp is a diversified financial services company with operations in Corporate Financial Services, Maintenance Leasing, Real Estate, PE Investment and Concession, Environment and Energy, Insurance, Banking and Credit, Aircraft and Ships, ORIX USA, ORIX Europe, Asia, and Australia and engages in various other fee businesses by providing products and services aligned with customer needs to its core customer base of domestic small and medium-sized enterprises. Orix's numerous divisions finance leases of large-ticket items like ships, airplanes, and technology equipment. The company generates the majority of its revenue from Corporate Financial Services and Maintenance Leasing operations and Real Estate operations.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.